Differentiating members of the thiazolidinedione class: A focus on efficacy

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue SUPPL. 2, 2002, Pages

  Goldstein, Barry J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Efficacy; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ANTIDIABETIC AGENT; DNA; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EXPERIMENTAL DESIGN; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALBUMINURIA; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036245330     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.251     Document Type: Article

References (35)

1. Rosiglitazone decreases insulin resistance and improves beta cell function in patients with type 2 diabetes
2. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats
3. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat
4. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent
5. Rates of hypoglycemia in users of sulfonylureas
6. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content
7. Rosiglitazone monotherapy is effective in patients with type 2 diabetes
8. Rosiglitazone produces long term reduction in urinary albumin excretion in patients with type 2 diabetes
9. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
10. Hepatic dysfunction associated with troglitazone
11. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radio-iodinated ligand for peroxisomal proliferator-activated receptor gamma
12. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators
13. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone
14. Rosiglitazone (BRL 49653) monotherapy has significant glucose-lowering effects in Type 2 diabetic patients
15. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
16. Pioglitazone is effective in the treatment of patients with type 2 diabetes
17. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
18. Rosiglitazone is effective in poorly controlled Type 2 diabetes patients
19. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in Type 2 diabetic patients
20. Rosiglitazone is an effective alternative to glibenclamide as first-line therapy in Type 2 diabetic patients
21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
22. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
23. Combination therapy with pioglitazone and sulfonylurea in patients with Type 2 diabetes
24. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes
25. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes
26. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
27. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
28. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
29. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated type 2 diabetes
30. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
31. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
32. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
33. Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes
34. Rosiglitazone is effective and well tolerated in patients ≥65 years with Type 2 diabetes
35. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin